| Filed On | Filing |
|---|---|
| 15 Feb 2024 |
8-K/A: Notice of Delisting or Failure to Satisfy a Listing Rule
On September 6, 2023, Cadrenal Therapeutics, Inc. (the “Company”) received a letter from The Nasdaq Stock Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Rule”), requiring listed... |
Loading...
